Celsion (NASDAQ:CLSN) surges 12% in premarket trading after the Data Safety Monitoring Board recommends that the company proceed to Phase 2 portion of its OVATION Study with the dose of 100 mg/m2.
The DSMB also determined that safety is
satisfactory with an acceptable risk/benefit, and that patients tolerate
up to 17 doses of GEN-1 during a course of treatment that lasts up to
six months. No dose limiting toxicities were reported.
The OVATION 2 Study combines GEN-1, Celsion’s
IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant
chemotherapy in patients newly diagnosed with Stage III/IV ovarian
cancer.
https://seekingalpha.com/news/3578666-celsion-jumps-12-after-getting-dsmb-go-ahead-for-ovation-phase-2
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.